OncoMatch/Clinical Trials/NCT06582940
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
Is NCT06582940 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for mri-guided adaptive radiotherapy.
This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain metastasis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy or excision for intracranial metastases
Previous radiotherapy or excision for intracranial metastases
Lab requirements
Blood counts
absolute neutrophil count≥ 500 cells/mm3; Platelet count≥50,000 cells/mm3; international normalized ratio(INR) ≤1.5; Prothrombin Time (PT)≤ 1.5 × ULN; Severe uncontrolled disease [excluded]
Kidney function
creatinine clearance rate(CCR) ≥45 mL/min; Urine protein 3-4+, or 24h urine protein quantitative >1g [excluded]
Liver function
Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN
Cardiac function
Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York class II or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months; Uncontrolled hypertension (systolic > 150mmHg and/or diastolic > 100mmHg)
Normal function of organs and bone marrow within 14 days: Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN; absolute neutrophil count≥ 500 cells/mm3; creatinine clearance rate(CCR) ≥45 mL/min; Platelet count≥50,000 cells/mm3; international normalized ratio(INR) ≤1.5#Prothrombin Time (PT)≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify